Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.70 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.70 |
| ▸ | KDR | P35968 | 2/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.70 |
| ▸ | FLT1 | P17948 | 1/20 | 0.70 |
| ▸ | FLT4 | P35916 | 1/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876398 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL4876401 | 0.92 | TGFBR1 (0.85) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL4868538 | 0.91 | TGFBR1 (0.83) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL14086498 | 0.91 | TGFBR1 (0.83) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL4872666 | 0.91 | TGFBR1 (0.83) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL4875690 | 0.90 | TGFBR1 (0.81) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL4876173 | 0.88 | TGFBR1 (0.78) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL1647719 | 0.87 | TGFBR1 (0.77) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL4870810 | 0.86 | TGFBR1 (0.76) | TGFBR1MAPK14PRKD1KDRPDGFRA | |
| SCHEMBL3176239 | 0.86 | TGFBR1 (0.75) | TGFBR1MAPK14PRKD1KDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245066-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2013-09-19 | — | — | US | claimed |
| US-20080319012-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | claimed |
| US-20130245066-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| US-20130245066-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| US-20130245066-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| US-20080319012-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | disclosed |
| US-20080319012-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | disclosed |
| US-20080319012-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245066-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ALK, ERBB4, ACVR1 | TGFBR1 93/4885MAPK14 478/4885PRKD1 2178/4885 |
| US-20080319012-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ALK, ERBB4, ACVR1 | TGFBR1 93/4885MAPK14 478/4885PRKD1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.